Abstract

BackgroundNon-islet cell tumor producing insulin-like growth factor 2 involves hypoglycemia. During tumor resection, intense fluctuation of blood glucose level may occur. An artificial endocrine pancreas has been reported as beneficial for patients with insulinoma as it maintains stable glycemic levels, although scarcely described with insulin-like growth factor 2-releasing tumor.Case presentationAn 84-year-old man had a recurrent left pleural solitary fibrous tumor releasing high molecular weight insulin-like growth factor 2 and experienced a frequent syncope accompanied by hypoglycemia. After anesthesia induction, an artificial endocrine pancreas, STG-55, was connected to the patient. Blood glucose level was stable at around 150 mg/dl during the resection surgery. The patient followed an uneventful course and was discharged without any complications.ConclusionsAn artificial endocrine pancreas may have the potential to stabilize the intraoperative blood glucose change in insulin-like growth factor 2-releasing tumor resection.

Highlights

  • Non-islet cell tumor producing insulin-like growth factor 2 involves hypoglycemia

  • Hypoglycemia mostly originates from diabetic therapy, including insulin and its secretagogues

  • The main pathophysiology of non-islet cell tumor hypoglycemia (NICTH) is the excessive release of Insulin-like growth factor 2 (IGF2) or the high molecular weight IGF2 [2], an incompletely processed precursor of IGF2

Read more

Summary

Conclusions

An artificial endocrine pancreas may have the potential to stabilize the intraoperative blood glucose change in insulin-like growth factor 2-releasing tumor resection.

Background
Discussion
Funding Unfunded
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call